| (UHN) OCTANE | Ontario-wide Cancer TArgeted Nucleic acid Evaluation (OCTANE) | Hotte, Dr Sebastien | Open | NCT02906943 |
| (Tesaro) 4010-01-001 / GARNET | A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors | Elit, Dr Laurie | Open | NCT02715284 |
| (Debio) 1143-NSCLC-105 | A phase-Ib dose-finding study of the SMAC mimetic Debio 1143 when given in combination with the anti-PD-L1 antibody avelumab to patients with advanced solid malignancies and, in an expansion cohort, to patients with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) after platinum-based therapy | Juergens, Dr Rosalyn | Open | NCT03270176 |
| (AstraZeneca) D4191C00068 / STRONG | An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies (STRONG) – Core Protocol; Module A – Post-Chemotherapy Urothelial and NonUrothelial Carcinoma of the Urinary Tract | Hotte, Dr Sebastien | Open | NCT03084471 |
Find a Trial
Contact Us